Ixekizumab

Drug Profile

Ixekizumab

Alternative Names: Anti-IL-17 MAb; Anti-IL-17 monoclonal antibody; IL-17 Ab; IL-17 antibody; Interleukin 17 antibody; LY-2439821; Taltz

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Registered Erythrodermic psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Ankylosing spondylitis; Spondylarthritis
  • Phase II Rheumatoid arthritis

Most Recent Events

  • 10 Mar 2017 Eli Lilly plans a phase I trial for Plaque psoriasis in China (NCT03073213)
  • 10 Mar 2017 Eli Lilly plans a phase III trial for Plaque psoriasis (In children, In adolescents) (NCT03073200)
  • 07 Mar 2017 Efficacy data and adverse event data from the phase III IXORA-S trial in Plaque psoriasis presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top